Key Takeaways
- Transformational quarter, driven by M&A: Revenue surged 162% YoY to ₹314 crores, with the newly acquired CrudeChem Technologies contributing the majority of the growth and shifting international revenue to 70% of the total.
- The $200 million ambition has been pulled forward: Management now expects to hit the $200 million revenue target before 2028, a significant acceleration from the prior 2030 expectation, fueled by the CCT acquisition and organic momentum.
- Profitability is a secondary priority to growth: While a blended EBITDA target of 18–20% was set, management explicitly prioritized capturing maximum business and market share, deferring a clear timeline for margin expansion.
- The order book provides high near-term visibility: Management described CCT's order book as "too strong enough even to comment," with Q4 performance established as the new baseline for future growth.
- What to watch next quarter: The pace of capacity expansion at CCT, any quantification of the $200 million revenue trajectory, and whether the textile segment's recovery translates into sustained volume growth.
The CCT Acquisition: A Step-Change in Scale
- Deal closed, integration underway: The acquisition of US-based CrudeChem Technologies Group in December 2025 immediately transformed Fineotex, adding a major oilfield chemicals platform and shifting the business mix so that Oil Specialty Chemicals now contribute 55–60% of revenue.
- Operational upgrades are the immediate priority: Post-acquisition, management initiated improvements in execution, capacity utilization, and supplier negotiations, with new machinery being installed within weeks to double manufacturing capacity and cater to larger contracts.
- The growth playbook is capital and technology: Fineotex provided growth capital and is transferring its own technologies to CCT, enabling the US entity to produce closer to Fortune 500 customers and win wallet share from competitors who had underinvested.
- A second stake purchase is already contracted: An agreement is in place for Fineotex to acquire a further 25% stake from CCT founders in January 2028, which would take its ownership to approximately 79–80%.
- The Q4 baseline is a floor, not a ceiling: Management stated that Q4's performance is the base going forward, with the order book described as exceptionally strong and things "getting much better than where it was before."
Tibrewala: "Right now, what has been experienced in the quarter four is something, which is the base what is already done. But already, as I see even now and going times, I think the order book is too strong enough even to comment right now."
Growth Ambition & Revenue Trajectory
- $200 million target accelerated by two years: The company's headline revenue ambition has been pulled forward from 2030 to "definitely before 2028," driven by the immediate scale and growth trajectory of the CCT business.
- A ₹3,000 crores top line is the next horizon: Management expressed high confidence in reaching this figure within 3–4 years, stating they would be "rather surprised if we don't touch it," implying a potential 3–4x increase from the current base.
- Wallet share offers a 5x runway without new customers: With existing marquee customers, management believes wallet share can easily increase fivefold, providing a deep growth reservoir independent of new client acquisition.
- CCT's steady-state is already sizable: Management indicated that CrudeChem can easily deliver a ₹600–₹650 crores top line on its own, forming a substantial base for the consolidated revenue target.
- Growth is being pursued organically and inorganically: Beyond CCT, the company is actively evaluating further M&A opportunities in the US and Middle East, with a new executive appointed to lead M&A and investor relations.
Tibrewala: "The wallet share increase with the kind of customers we have right now, forget about adding more customers, can easily go to 5x."
Segment Dynamics: Oilfield Surges, Textile Recovers
- Oil & Gas becomes the dominant segment: The CCT acquisition propelled Oil Specialty Chemicals to 55–60% of Q4 revenue, with the North American market growing rapidly and new regions like Suriname, Guyana, and Venezuela emerging.
- CCT's competitive moat is service and customization: The business combines specialty chemical manufacturing with technical services and critical last-mile delivery, offering products tailor-made for extreme US field conditions, from -20°C to 45°C.
- Textile faced a decade-low year but is turning: FY26 was described as one of the worst years for the textile industry due to geopolitical issues, yet volumes have already picked up from April onwards, with volume growth of 15% reported.
- India's textile sector has structural tailwinds: New trade treaties with the UK, EU, and USA, combined with competitive fuel costs versus Pakistan and Bangladesh, are expected to strengthen Indian export competitiveness and benefit domestic producers.
- Textile's revenue share fell on relative growth, not decline: The segment's contribution dropped to 35–36% of total revenue not because it shrank, but because the oilfield business grew much faster, while textile itself continued to grow.
Margin & Profitability: Growth First, Margins Later
- A 15% EBITDA floor is the near-term comfort zone: Management stated that going forward, the company should "comfortably" be at an EBITDA of 15% or more, setting a baseline expectation post-acquisition.
- An 18–20% blended target exists, but without urgency: The aspirational blended EBITDA target of 18–20% was described as "easy" and "achievable," potentially even within FY27, but management stressed that driving business and capturing market share is the immediate priority.
- Operational improvements are already lifting CCT's margins: Post-acquisition, EBITDA margins at CCT are improving considerably due to better resource allocation, machinery investments, manpower additions, and renegotiated supplier terms.
- Working capital is elevated by design: The working capital cycle stands at 79 days, with management defending higher inventory levels as necessary to navigate raw material uncertainty and global logistics delays, calling a sub-90-day cycle "best practice."
- The negative operating cash flow is a one-time artifact: The full-year negative OCF resulted from an accounting policy that deducts acquisition investments from operational cash flow; management assured this is a one-time entry and positive cash flows will resume.
Tibrewala: "On a blended level, we would always look at getting to an easy EBITDA of around 18% to 20%, and that's what we are heading to. I think it's not too far from now, but what's more important right now is to drive the businesses and take the maximum businesses in control."
Operational Capacity & Global Expansion
- CCT capacity is being doubled immediately: New machines have been ordered and are being installed within weeks to double manufacturing capacity, enabling the company to onboard new customers and accelerate growth in high-margin specialty oilfield chemicals.
- R&D investment is scaling dramatically: Since the acquisition, R&D expenditures and team size have increased significantly at CCT's Midland facility, with new PhD hires and additional resources to sustain growth rates.
- Overall plant utilization has headroom: Consolidated capacity utilization stood at 60–62% in Q4, with further increases expected in Q1 as the Ambernath plant benefits from the textile volume recovery.
- The Middle East is the next frontier: A Fineotex team is currently in Oman exploring opportunities, and the company is considering inorganic acquisition opportunities in the region through its existing UAE subsidiary, shifting from a greenfield plant plan.
- Logistics headwinds are receding: Global freight cost and container shortages created challenges in Q4 and April, but management stated the worst is behind them, with the team successfully passing on costs and realigning inventory levels.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | Reach $200 million consolidated revenue | Before 2028 |
| Revenue target | Reach ₹3,000 crores top line | 3–4 years |
| CCT capacity | Double manufacturing capacity at CrudeChem | Machines being installed in weeks |
| CCT stake increase | Acquire further 25% stake from founders, taking ownership to ~79-80% | January 2028 |
| Blended EBITDA margin | Achieve 18% to 20% blended EBITDA | Could reflect in FY27 |
| Near-term EBITDA floor | Comfortably at 15% EBITDA or more | Going forward |
| CCT steady-state revenue | CCT to deliver ₹600–₹650 crores top line | Steady-state (no date) |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | ₹314 cr, +162% YoY |
| Profit after tax | ₹44 cr, +118% YoY (₹20 cr in Q4 FY25) |
| International revenue contribution | 70% of total revenue |
| ROIC | 31% |
| Working capital cycle | 79 days |
| Consolidated EBITDA margin | 14% |
| Blended EBITDA margin target | 18% to 20% going forward |
| Textile specialty revenue growth | ~8% YoY (Q4 FY26 vs Q4 FY25) |
| Textile volume growth | 15% |
| Textile revenue contribution | 35% to 36% of total revenue |
| Oil specialty chemicals revenue contribution | 55% to 60% of total revenue |
| CrudeChem Q4 revenue | ₹165–170 cr |
| CrudeChem annualized revenue run rate | $90 mn to $100 mn (per an analyst's math) |
| CrudeChem revenue target | $200 mn, revised from 2030 to before 2028 |
| CrudeChem EBITDA margin target | 15% more or less going forward |
| CrudeChem North American addressable market | $3.5 bn to $4 bn |
| CrudeChem working capital cycle | 80–85 days |
| Post-acquisition capex in CrudeChem | ~$7 mn invested, further ~$7 mn extended |
| Cash on books | >₹300 cr post-acquisition and investments |
| Plant-level utilization | 60% to 62% broadly on Q4 numbers |
| Stake increase in CrudeChem | Additional 25% to be acquired in January 2028, taking stake to ~79% to 80% |
| Indian textile exports FY26 | ₹3.16 trillion, +2.1% YoY |